Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler®

O. Johnell, R. Pauwels, C-G. Löfdahl, L.A. Laitinen, D.S. Postma, N.B. Pride, S.V. Ohlsson
European Respiratory Journal 2002 19: 1058-1063; DOI: 10.1183/09031936.02.00276602
O. Johnell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Pauwels
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C-G. Löfdahl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L.A. Laitinen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D.S. Postma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N.B. Pride
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.V. Ohlsson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Fig. 1.—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.—

    Mean changes in bone mineral density (BMD) during the study, measured in a) lumbar spine (L2–L4), b) femoral neck, c) femoral trochanter and d) femoral Ward's triangle. ▪: budesonide 400 µg b.i.d.; •: placebo.

Tables

  • Figures
  • Table 1

    Baseline demographic characteristics of the radiograph (n=653) dual-energy X-ray absorptiometry (DEXA, n=161) and overall (n=912) study populations

    RadiographDEXAOverall study population
    BudesonidePlaceboBudesonidePlaceboBudesonidePlacebo
    Subjects n3223318279458454
    Age yrs52 (31–65)52 (25–65)54 (31–64)53 (36–64)52 (31–65)52 (25–65)
    Height cm173.0 (152–194)172.9 (150–198)172.3 (155–189)172.1 (154–192)172.8 (152–194)172.8 (150–198)
    Weight kg75.5 (41–121)73.7 (43–125)77.4 (50–117)74.8 (50–110)74.9 (41–121)73.6 (43–125)
    Duration of smoking yrs35.5 (11–52)35.7 (9–56)36.2 (11–50)36.4 (20–51)36.0 (11–52)36.0 (9–56)
    Total consumption g·day−114.8 (1.5–45)13.5 (0.8–103.1)16.1 (1.5–33.8)16.3 (3.8–52.5)1.50 (1.5–88.7)13.7 (0.8–103.1)
    Cigarettes·day−119.3 (0–60)17.1 (0–70)21.0 (0–45)20.9 (3–70)19.1 (0–60)17.6 (0–70)
    • Data are presented as mean (range)

  • Table 2

    Baseline bone mineral density in patients for whom both baseline and end-of-treatment scans were available (n=16)

    BudesonidePlacebo
    Subjects n8279
    Femoral neck g·cm20.89±0.15 (0.59–1.26)0.85±0.16 (0.57–1.33)
    Femoral trochanter g·cm20.79±0.16 (0.38–1.21)0.77±0.17 (0.45–1.22)
    Femoral Ward’s triangle g·cm20.69±0.19 (0.35–1.14)0.66±0.20 (0.31–1.27)
    L2–L4 g·cm21.09±0.17 (0.58–1.59)1.06±0.19 (0.67–1.60)
    • Data are presented as mean ± sd (range)

  • Table 3

    Baseline bone mineral density at the end of the study

    BudesonidePlacebo
    Subjects n7871
    Femoral neck g·cm20.88±0.15 (0.57–1.27)0.85±0.15 (0.54–1.29)
    Femoral trochanter g·cm20.78±0.16 (0.33–1.19)0.77±0.17 (0.48–1.22)
    Femoral Ward’s triangle g·cm20.68±0.18 (0.30–1.12)0.66±0.18 (0.34–1.20)
    L2–L4 g·cm21.09±0.19 (0.56–1.68)#1.06±0.19 (0.70–1.61)¶
    • Data are presented as mean±sd (range)

    • #: n=82

    • ¶: n=79

  • Table 4

    Estimated difference in treatment effects on bone mineral density (budesonide and placebo)

    Estimated differenceLower 95% CIUpper 95% CIp-value
    L2–L4 % change−0.52−1.910.880.4667
    Femoral neck % change−0.87−2.580.850.3205
    Femoral trochanter % change−1.62−3.490.250.0895
    Femoral Ward’s triangle % change−1.67−4.841.500.2987
    • CI: Confidence interval

PreviousNext
Back to top
View this article with LENS
Vol 19 Issue 6 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler®
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler®
O. Johnell, R. Pauwels, C-G. Löfdahl, L.A. Laitinen, D.S. Postma, N.B. Pride, S.V. Ohlsson
European Respiratory Journal Jun 2002, 19 (6) 1058-1063; DOI: 10.1183/09031936.02.00276602

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler®
O. Johnell, R. Pauwels, C-G. Löfdahl, L.A. Laitinen, D.S. Postma, N.B. Pride, S.V. Ohlsson
European Respiratory Journal Jun 2002, 19 (6) 1058-1063; DOI: 10.1183/09031936.02.00276602
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Alterations in gene expression in hamster diaphragm after emphysema and lung volume reduction surgery
  • Resistance versus endurance training in patients with COPD and peripheral muscle weakness
  • Contribution of respiratory acidosis to diaphragmatic fatigue at exercise
Show more Original Articles: COPD/Rehabilitation/Respiratory Muscles

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society